United States: FDA Issues Draft Guidances For Prior Approval Supplements And Amendments / Easily Correctable Deficiencies Under GDUFA

The Generic Drug User Fee Amendments of 2012 (GDUFA) were signed into law on July 9, 2012, in an effort "to speed access to safe and effective generic drugs to the public and reduce costs to industry." In July 2014, the U.S. Food and Drug Administration (FDA) issued two draft Guidances for Industry: one relating to Prior Approval Supplements Under GDUFA and one relating to Amendments and Easily Correctable Deficiencies Under GDUFA.

Prior Approval Supplements Under GDUFA

Prior approval supplements (PASs) and amendments to PASs for abbreviated new drug applications (ANDAs) are submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(j)). The FDA issued the following performance metric goals for PASs submissions:

  • If an inspection is not needed, the goal is six months from the date of submission.
  • If an inspection is needed, the goal is 10 months from the date of submission.

The FDA hopes to review and act on 60 percent of PAS submissions in fiscal year 2015, 75 percent of PAS submissions in fiscal year 2016 and 90 percent of PAS submissions in fiscal year 2017. However, these performance metric goals apply only to ANDA holders that submit a PAS on or after October 1, 2014. They do not apply to an amendment to a PAS if the PAS was submitted prior to that date. These performance metric goals also do not apply to new drug applications or biologics license applications or to supplements thereto. If an amendment is made to a PAS, the GDUFA goal date may be revised by the FDA.

The submission date is defined as the date that the PAS arrives in the appropriate electronic portal of the FDA. The FDA will then count this submission date as the first day of the review period and will calculate the goal date in months. If FDA refuses to receive a PAS, the GDUFA review clock will stop. The applicant can then submit a corrected or new supplement, but a new GDUFA fee will be required and a new review clock will start, resulting in a new goal date for that PAS.

The following events can result in the FDA's refusal to receive a PAS:

  • failure to pay the application fee within 20 calendar days of submission;
  • reference to a drug master file (DMF) that is not on the public available for reference list;
  • reference to a facility on the facility arrears list;
  • the applicant is the owner or is affiliated with the owner of a facility on the facility arrears list; or
  • the applicant is on or affiliated with an entity on the backlog arrears list.

If a PAS is substantially complete except for failure to pay the PAS user fee, the PAS will be deemed received when the fee is paid. Similarly, if a PAS is substantially complete but references a facility on the arrears list, the PAS will be deemed received once the facility is removed from that list.

Determining whether an inspection is required for a PAS is within the discretion of the FDA and depends, in part, on the nature of the supplement. If the PAS involves a facility not approved in the original ANDA or if it involves a fundamental change to the manufacturing process or technology, an inspection may be required. FDA, however, will rely on previous inspections of a finished product site if it occurred within two years of the current Good Manufacturing Practice (cGMP) evaluation for a pending application, three years for an active pharmaceutical ingredient (API) site or control testing laboratory and four years for a packaging-only site. Some exceptions may apply to this general practice, depending on the nature of the drug being processed or the complexity of the processing operations.

The FDA considers multiple supplements submitted to multiple ANDAs by a single applicant for the same chemistry, manufacturing and controls change to each ANDA to be a "grouped supplement." However, each supplement in this group is considered an individual submission and requires its own GDUFA fee for each ANDA in the group. That being said, the submissions will generally have the same GDUFA goal date.

If a supplement is filed as a Changes Being Effected (CBE) but the FDA finds that such submission should have been submitted as a PAS, the FDA will notify the applicant and then administratively close and withdraw the CBE. The applicant may then resubmit the supplement as a PAS, along with the required GDUFA fee. The GDUFA review clock will run from the date of submission of the PAS.

Amendments and Easily Correctible Deficiencies Under GDUFA

The FDA has issued the following performance metric goals for amendments submitted electronically to original ANDAs and PASs filed on or after October 1, 2014.

For original ANDAs or PASs submitted before October 1, 2014, these performance goals are inapplicable to subsequently filed amendments thereto. Where these goals apply, such amendments may add additional time to the original ANDA review, but in no case will they shorten the original goal date. The time periods above are calculated from the date of submission of the amendment.

"A solicited amendment is a submission made by an applicant in response to a complete response letter (CR) issued by FDA." These amendments are classified as either Tier 1 or Tier 3 and either as a major amendment, a minor amendment or an easily correctable deficiency (ECD). A major amendment "contain[s] a substantial amount of new data or new information not previously submitted to reviewed by FDA, requiring ... a substantial expenditure of FDA resources." The first solicited major amendment is classified as Tier 1; any subsequent major amendment is classified as Tier 3. Appendix A of the Draft Guidance provides a nonexhaustive list of deficiencies that generally require major amendments. A minor amendment, on the other hand, "requires ... fewer FDA resources than are necessary to review a major amendment but more than are necessary to review the information submitted in response to an ECD." For instance, a minor amendment may address missing information but not require any new studies to be performed. The first through fifth solicited minor amendments are classified as Tier 1; any subsequent minor amendment is classified as Tier 3. Appendix B of the Draft Guidance provides a nonexhaustive list of deficiencies that generally require minor amendments. Any Tier 3 amendment, whether major or minor, will cause the ANDA to lose its goal date. Finally, ECDs "require[] ... a modest expenditure of FDA resources." They can be responded to quickly because the applicant should already have the necessary information. ECDs generally relate to requests for clarification, requests for postapproval commitments or final resolution of technical issues. ECDs do not extend the goal date. Appendix C of the Draft Guidance provides a nonexhaustive list of deficiencies that are generally ECDs.

"An unsolicited (gratuitous) amendment is submitted on the applicant's own initiative and not in response to FDA's CR letter." These amendments are classified as either delaying or nondelaying. All delaying amendments are Tier 1 and all non-delaying amendments are Tier 2. A delaying amendment "address[es] actions by a third party that would cause delay or impede application review or approval timing and that were not a factor at the time of submission." Delaying amendments do not add to the count of major or minor amendments. A nondelaying amendment "contain[s] information that is not requested by FDA and is not the result of changes to the RLD or USP monograph, changes to the RLD labeling, a REMS and REMS modification, or generic approval requirements reflected in citizen petition responses issued by FDA."

By contrast, an administrative amendment is "routine in nature and do[es] not require scientific review." These types of amendments include "[r]equests for final approval with no scientific changes to the ANDA, patent amendments, and general correspondence submitted by applicants." These amendments do not affect goal dates.

An applicant may request reconsideration of an amendment classification. If an applicant seeks reconsideration of a CR amendment, a written request for a post-CR-letter meeting must be sent to the regulatory project manager within 10 business days of issuance of the CR letter. The applicant will then be required to submit meeting materials that adequately explain the nature of the request. The division will issue a decision within 10 business days. If the request is granted after an amendment has been submitted and a review is pending, the change in classification will not alter the goal date but will adjust the amendment count. If the amendment has not yet been submitted, it will be assigned the revised classification and corresponding goal date. If an applicant seeks reconsideration of a change in classification after submission of a CR amendment, the request should be made in writing within 10 business days from issuance of the goal letter and contain adequate information to explain the nature of the dispute. The division will make a decision on this request within 10 business days, and if rendered, such a change in classification will not alter the goal date but will adjust the amendment count. If an applicant disagrees with the decision on reconsideration, it may file a formal appeal of the decision.

The Draft Guidance provides a series of useful examples for how these amendment goals are applied. It also provides an amendment flow chart that graphically depicts the different types of amendments and their effect on the goal date.

If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Carolyn A. Alenci, any member of the Pharmaceutical, Medical Device, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.